Abstract
Human urotensin-II (U-II) is an 11-amino-acid cyclic peptide that activates a Gq-coupled receptor named UT. Little is known about the desensitisation profile of this receptor as peptide binding is essentially irreversible. In the present study, we have examined the effects of U-II and carbachol on Ca2+ signalling in SJCRH30 rhabdomyosarcoma (receptor density, Bmax ~0.1 pmol/mg protein) and human embroynic kidney (HEK)hUT (B max ~1.4 pmol/mg protein) cells expressing native and recombinant UT, respectively. In SJCRH30, HEKhUT and human peripheral blood mononuclear cells induced to express native UT by treatment with 2 μg/ml lipopolysaccharide (LPS), we have measured the effects of U-II treatment on UT mRNA. In SJCRH30 cells, primary stimulation with carbachol (250 μM) did not affect a secondary challenge with U-II (1 μM) and primary challenge with U-II did not affect a secondary challenge with carbachol. In contrast, in HEKhUT cells, primary stimulation with carbachol (250 μM) reduced a secondary challenge to U-II (1 μM) by 84% and primary challenge with U-II reduced a secondary challenge to carbachol by 76%. Pre-treatment of SJCRH30 cells with U-II reduced UT mRNA after 6 h and this returned to basal after 24 h. In recombinant HEKhUT cells, UT mRNA expression increased following a 6 h treatment with 1 μM U-II. U-II treatment of naïve un-stimulated peripheral blood mononuclear cells was without effect. However, when UT expression is up-regulated following 15 h of LPS treatment, a 6 h U-II challenge reduced UT mRNA by 66%. In summary, we report differences in the desensitisation profiles of native and recombinant U-II receptors. Design and interpretation of functional experiments are hampered by irreversibility of U-II binding.
Similar content being viewed by others
References
Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Douglas SA et al (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401:282–286
Ancellin N, Preisser L, Le Maout S, Barbado M, Creminon C, Corman B, Morel A (1999) Homologous and heterologous phosphorylation of the vasopressin V1a receptor. Cell Signal 11:743–751
Barnes TA, McDonald J, Rowbotham DJ, Duarte TL, Lambert DG (2007) Effects of receptor density on Nociceptin/OrphaninFQ peptide receptor desensitisation: studies using the ecdysone inducible expression system. Naunyn Schmiedebergs Arch Pharmacol 376:217–225
Bern HA, Lederis K (1969) A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts. J Endocrinol 45(Suppl):xi–xii
Brailoiu E, Jiang X, Brailoiu GC, Yang J, Chang JK, Wang H, Dun NJ (2008) State-dependent calcium mobilization by urotensin-II in cultured human endothelial cells. Peptides 29:721–726
Bundey RA, Nahorski SR (2001) Homologous and heterologous uncoupling of muscarinic M(3) and alpha(1B) adrenoceptors to Galpha(q/11) in SH-SY5Y human neuroblastoma cells. Br J Pharmacol 134:257–264
Camarda V, Rizzi A, Calo G, Gendron G, Perron SI, Kostenis E, Zamboni P, Mascoli F, Regoli D (2002) Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol 365:141–149
Chen YL, Liu JC, Loh SH, Chen CH, Hong CY, Chen JJ, Cheng TH (2008) Involvement of reactive oxygen species in urotensin II-induced proliferation of cardiac fibroblasts. Eur J Pharmacol 593:24–29
Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159
Cosenzi A (2008) Non peptidic urotensin II antagonists: perspectives for a new class of drugs. Cardiovasc Hematol Agents Med Chem 6:80–91
Douglas SA, Ashton DJ, Sauermelch CF, Coatney RW, Ohlstein DH, Ruffolo MR, Ohlstein EH, Aiyar NV, Willette RN (2000) Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol 36:S163–S166
Douglas SA, Dhanak D, Johns DG (2004a) From ‘gills to pills’: urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 25:76–85
Douglas SA, Naselsky D, Ao Z, Disa J, Herold CL, Lynch F, Aiyar NV (2004b) Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines. Br J Pharmacol 142:921–932
Filipeanu CM, Brailoiu E, Le Dun S, Dun NJ (2002) Urotensin-II regulates intracellular calcium in dissociated rat spinal cord neurons. J Neurochem 83:879–884
Fontes-Sousa AP, Brás-Silva C, Pires AL, Monteiro-Sousa D, Leite-Moreira AF (2007) Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling. Naunyn Schmiedebergs Arch Pharmacol 376:107–115
Grynkiewicz G, Poenie M, Tsien RY (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440–3450
Hirst RA (2006) Measurement of [Ca2+]i in whole cell suspensions using fura-2. Methods Mol Biol 312:37–45
Leprince J, Chatenet D, Dubessy C, Fournier A, Pfeiffer B, Scalbert E, Renard P, Pacaud P, Oulyadi H, Segalas-Milazzo I, Guilhaudis L, Davoust D, Tonon MC, Vaudry H (2008) Structure-activity relationships of urotensin II and URP. Peptides 29:658–673
Lescot E, Bureau R, Rault S (2008) Nonpeptide urotensin-II receptor agonists and antagonists: review and structure-activity relationships. Peptides 29:680–690
McDonald J, Barnes TA, Okawa H, Williams J, Calo G, Rowbotham DJ, Lambert DG (2003) Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system. Br J Pharmacol 140:61–70
McDonald J, Batuwangala M, Lambert DG (2007) Role of urotensin II and its receptor in health and disease. J Anesth 21:378–389
Mellstrom B, Savignac M, Gomez-Villafuertes R, Naranjo JR (2008) Ca2+-operated transcriptional networks: molecular mechanisms and in vivo models. Physiol Rev 88:421–449
Mundell SJ, Pula G, More JC, Jane DE, Roberts PJ, Kelly E (2004) Activation of cyclic AMP-dependent protein kinase inhibits the desensitization and internalization of metabotropic glutamate receptors 1a and 1b. Mol Pharmacol 65:1507–1516
Onan D, Hannan RD, Thomas WG (2004) Urotensin II: the old kid in town. Trends Endocrinol Metab 15:175–182
Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853–6866
Russell FD, Molenaar P (2004) Cardiovascular actions of human urotensin II—considerations for hypertension. Naunyn Schmiedebergs Arch Pharmacol 369:271–273
Segain JP, Rolli-Derkinderen M, Gervois N, Raingeard de la Bletiere D, Loirand G, Pacaud P (2007) Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol 179:901–909
Song W, McDonald J, Camarda V, Calo G, Guerrini R, Marzola E, Thompson JP, Rowbotham DJ, Lambert DG (2006) Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity. Naunyn Schmiedebergs Arch Pharmacol 373:148–157
Sprague J, Harrison C, Rowbotham DJ, Smart D, Lambert DG (2001) Temperature-dependent activation of recombinant rat vanilloid VR1 receptors expressed in HEK293 cells by capsaicin and anandamide. Eur J Pharmacol 423:121–125
Sue YM, Chen CH, Hsu YH, Hou CC, Cheng CY, Chen YC, Lin SL, Chen TW, Chen TH (2009) Urotensin II induces transactivation of the epidermal growth factor receptor via transient oxidation of SHP-2 in the rat renal tubular cell line NRK-52E. Growth Factors 27:155–162
Williams JP, Thompson JP, McDonald J, Barnes TA, Cote T, Rowbotham DJ, Lambert DG (2007) Human peripheral blood mononuclear cells express nociceptin/orphanin FQ, but not mu, delta, or kappa opioid receptors. Anesth Analg 105:998–1005 table of contents
Williams JP, Thompson JP, Rowbotham DJ, Lambert DG (2008) Human peripheral blood mononuclear cells produce pre-pro-nociceptin/orphanin FQ mRNA. Anesth Analg 106:865–866 table of contents
Acknowledgements
MB holds a Leicester-Ferrara International PhD studentship. PCR equipment was provided by a grant from British Journal of Anaesthesia / Royal College of Anaesthetists. This paper is dedicated to the memory of Stephen A. Douglas, an outstanding ‘Urotensin scientist’ and a good friend.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Batuwangala, M.S., Calo, G., Guerrini, R. et al. Desensitisation of native and recombinant human urotensin-II receptors. Naunyn-Schmied Arch Pharmacol 380, 451–457 (2009). https://doi.org/10.1007/s00210-009-0441-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-009-0441-9